Abstract
Oligometastatic disease is a separate category of metastatic prostate cancer. In recent years, more and more attention has been focused on its optimal definition and treatment.
Central to the identification of oligometastatic prostate cancer is not only the number and location of metastases, but also the use of new imaging methods in their identification. Treatment of oligometastatic prostate cancer may have curative potential.
It includes systemic and radical local treatment, which can be targeted at both primary tumors and metastases. Radiotherapy, especially the technique of stereotactic radiotherapy, is more widely used as a locally ablative treatment.
In this case, topical treatment not only prevents local disease progression, but also improves overall survival. The boundaries between curative and palliative treatment are thus constantly shifting.
Better identification of patients who will benefit from topical treatment and better classification of oligometastatic prostate cancer subgroups based on biomolecular markers is the task of further studies.